Revenue by source
Revenue Net$0.00Oncology$747.59MMetabolic$744.96MOther$408.55MCardiology$239.37MCentral Nervous System$254.84MAntiviral And Anti Infective$134.94MEndocrine$0.00Medical Devices$0.00
| Segment | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Revenue Net | $15.10M | $18.90M | $15.90M | $34.50M | $1.46B | $1.89B | - | - |
| Oncology | $189.03M | $256.77M | - | $362.85M | $467.80M | $587.10M | $651.24M | $747.59M |
| Metabolic | $94.13M | $138.65M | - | $159.90M | $244.68M | $376.84M | $457.54M | $744.96M |
| Other | $161.19M | $222.51M | - | $267.42M | $296.91M | $404.84M | $431.38M | $408.55M |
| Cardiology | $91.82M | $91.26M | - | $119.69M | $174.63M | $193.69M | $230.45M | $239.37M |
| Central Nervous System | $53.90M | $65.39M | - | $121.55M | $157.94M | $160.06M | $181.98M | $254.84M |
| Antiviral And Anti Infective | $76.74M | $86.39M | - | $110.98M | $118.03M | $163.31M | $156.46M | $134.94M |
| Endocrine | $26.00M | - | - | - | - | - | - | - |
| Medical Devices | $11.77M | - | - | - | - | - | - | - |